/
enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on mainstreaming gene therapy through non-viral delivery of therapeutics to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid (detalimogene), targets non-muscle invasive bladder cancer (NMIBC), particularly in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS), with or without papillary disease. This therapy is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, including a pivotal cohort. enGene Therapeutics Inc. leverages its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables localized delivery of diverse gene cargos such as DNA and various forms of RNA directly to target tissues. Operating in the biotechnology and medical research sector, the company addresses diseases with high unmet clinical needs by developing genetic medicines that penetrate mucosal barriers effectively. Headquartered in Saint-Laurent, Quebec, Canada, enGene Therapeutics Inc. plays a role in advancing innovative treatments for oncology and other challenging indications through its DDX technology.
$1.79
+$0.02 (+1.41%)
Live · 02:15 PM · Twelve Data
ROIC dropped from -25.91% to -39.14%, capital efficiency is deteriorating. Negative free cash flow of -$101M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$127M
▼ -112.7% YoY
Op. Margin
—
ROIC
-39.14%
▼ -13.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$111M
▼ -104.7% YoY
Op. Cash Flow (TTM)
-$105M
▼ -115.3% YoY
Net Debt
-$162M
Net Cash Position
Cash & Equiv.
$194M
Continue Research
enGene Therapeutics (ENGN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, enGene Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
enGene Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -39.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ENGN's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.